

# Benign Prostatic Hyperplasia (BPH) Medication Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/B845A5150755EN.html>

Date: March 2022

Pages: 127

Price: US\$ 3,250.00 (Single User License)

ID: B845A5150755EN

## Abstracts

BPH (benign prostatic hyperplasia, BPH) is a common disease and frequently encountered disease in older men, main show is prostate of glands and stroma hyperplasia, prostate enlargement, lower urinary tract symptoms (the lower urinary tract symptom, LUTS), and bladder outlet obstruction. There are currently three major classes of drugs for BPH: 5-beta-reductase inhibitors, such as finasteride; Beta-blockers, such as terazosin hydrochloride, doxazosin mesylate, etc. Herbal preparations and Chinese medicine, such as the general, etc.

This report contains market size and forecasts of Benign Prostatic Hyperplasia (BPH) Medication in global, including the following market information:

Global Benign Prostatic Hyperplasia (BPH) Medication Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Benign Prostatic Hyperplasia (BPH) Medication Market Sales, 2017-2022, 2023-2028, (KG)

Global top five Benign Prostatic Hyperplasia (BPH) Medication companies in 2021 (%)

The global Benign Prostatic Hyperplasia (BPH) Medication market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

5-Alpha-Reductase Inhibitors Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Benign Prostatic Hyperplasia (BPH) Medication include Astellas Pharma, Eli Lilly, GlaxoSmithKline, Sanofi, ADC Therapeutics, Bayer HealthCare, Bristol-Myers Squibb, Valeant Pharmaceuticals and Endo Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Benign Prostatic Hyperplasia (BPH) Medication manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Benign Prostatic Hyperplasia (BPH) Medication Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (KG)

Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment Percentages, by Type, 2021 (%)

5-Alpha-Reductase Inhibitors

Beta-Blockers

Botanicals and Traditional Chinese Medicine

Global Benign Prostatic Hyperplasia (BPH) Medication Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (KG)

Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment Percentages, by Application, 2021 (%)

Hospital Pharmacies

Retail Pharmacies

## Online Pharmacies

Global Benign Prostatic Hyperplasia (BPH) Medication Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (KG)

Global Benign Prostatic Hyperplasia (BPH) Medication Market Segment Percentages, By Region and Country, 2021 (%)

### North America

US

Canada

Mexico

### Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

### Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Benign Prostatic Hyperplasia (BPH) Medication revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Benign Prostatic Hyperplasia (BPH) Medication revenues share in global market, 2021 (%)

Key companies Benign Prostatic Hyperplasia (BPH) Medication sales in global market, 2017-2022 (Estimated), (KG)

Key companies Benign Prostatic Hyperplasia (BPH) Medication sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Merck

Novartis

Advaxis

Teva Pharmaceutical Industries

Urologixs

Agennix

ANI Pharmaceuticals

BHR Pharma

Boehringer Ingelheim

Sanpower Group

Eisai

Ferring

IO THERAPEUTICS

LIDDS

Madrigal Pharmaceuticals

Nymox Pharmaceutical

Spectrum Pharmaceuticals

Takeda Pharmaceuticals

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Benign Prostatic Hyperplasia (BPH) Medication Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION OVERALL MARKET SIZE**

- 2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size: 2021 VS 2028
- 2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales: 2017-2028

### **3 COMPANY LANDSCAPE**

- 3.1 Top Benign Prostatic Hyperplasia (BPH) Medication Players in Global Market
- 3.2 Top Global Benign Prostatic Hyperplasia (BPH) Medication Companies Ranked by Revenue
- 3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Companies
- 3.4 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Companies
- 3.5 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Manufacturer (2017-2022)
- 3.6 Top 3 and Top 5 Benign Prostatic Hyperplasia (BPH) Medication Companies in Global Market, by Revenue in 2021
- 3.7 Global Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type
- 3.8 Tier 1, Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Medication Players in Global Market
  - 3.8.1 List of Global Tier 1 Benign Prostatic Hyperplasia (BPH) Medication Companies

### 3.8.2 List of Global Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Medication Companies

## 4 SIGHTS BY PRODUCT

### 4.1 Overview

4.1.1 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Markets, 2021 & 2028

4.1.2 5-Alpha-Reductase Inhibitors

4.1.3 Beta-Blockers

4.1.4 Botanicals and Traditional Chinese Medicine

4.2 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue & Forecasts

4.2.1 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2022

4.2.2 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2023-2028

4.2.3 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

4.3 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales & Forecasts

4.3.1 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2022

4.3.2 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2023-2028

4.3.3 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

4.4 By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Price (Manufacturers Selling Prices), 2017-2028

## 5 SIGHTS BY APPLICATION

### 5.1 Overview

5.1.1 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2021 & 2028

5.1.2 Hospital Pharmacies

5.1.3 Retail Pharmacies

5.1.4 Online Pharmacies

5.2 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue & Forecasts



5.2.1 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2022

5.2.2 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2023-2028

5.2.3 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

5.3 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales & Forecasts

5.3.1 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2022

5.3.2 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2023-2028

5.3.3 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

5.4 By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Price (Manufacturers Selling Prices), 2017-2028

## **6 SIGHTS BY REGION**

6.1 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2021 & 2028

6.2 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue & Forecasts

6.2.1 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2022

6.2.2 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2023-2028

6.2.3 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

6.3 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales & Forecasts

6.3.1 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2022

6.3.2 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales, 2023-2028

6.3.3 By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Benign Prostatic Hyperplasia (BPH) Medication

## Revenue, 2017-2028

### 6.4.2 By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2028

#### 6.4.3 US Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.4.4 Canada Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.4.5 Mexico Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

## 6.5 Europe

### 6.5.1 By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2028

### 6.5.2 By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2028

### 6.5.3 Germany Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.5.4 France Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.5.5 U.K. Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.5.6 Italy Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.5.7 Russia Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

### 6.5.8 Nordic Countries Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

### 6.5.9 Benelux Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

## 6.6 Asia

### 6.6.1 By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2028

### 6.6.2 By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2028

#### 6.6.3 China Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.6.4 Japan Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

### 6.6.5 South Korea Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

### 6.6.6 Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.6.7 India Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

## 6.7 South America

### 6.7.1 By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2028

### 6.7.2 By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2028

#### 6.7.3 Brazil Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

#### 6.7.4 Argentina Benign Prostatic Hyperplasia (BPH) Medication Market Size,

2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, 2017-2028

6.8.3 Turkey Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

6.8.4 Israel Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

6.8.5 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

6.8.6 UAE Benign Prostatic Hyperplasia (BPH) Medication Market Size, 2017-2028

## **7 MANUFACTURERS & BRANDS PROFILES**

7.1 Astellas Pharma

7.1.1 Astellas Pharma Corporate Summary

7.1.2 Astellas Pharma Business Overview

7.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings

7.1.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)

7.1.5 Astellas Pharma Key News

7.2 Eli Lilly

7.2.1 Eli Lilly Corporate Summary

7.2.2 Eli Lilly Business Overview

7.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings

7.2.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)

7.2.5 Eli Lilly Key News

7.3 GlaxoSmithKline

7.3.1 GlaxoSmithKline Corporate Summary

7.3.2 GlaxoSmithKline Business Overview

7.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings

7.3.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)

7.3.5 GlaxoSmithKline Key News

7.4 Sanofi

7.4.1 Sanofi Corporate Summary

- 7.4.2 Sanofi Business Overview
- 7.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
- 7.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
- 7.4.5 Sanofi Key News
- 7.5 ADC Therapeutics
  - 7.5.1 ADC Therapeutics Corporate Summary
  - 7.5.2 ADC Therapeutics Business Overview
  - 7.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.5.4 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.5.5 ADC Therapeutics Key News
- 7.6 Bayer HealthCare
  - 7.6.1 Bayer HealthCare Corporate Summary
  - 7.6.2 Bayer HealthCare Business Overview
  - 7.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.6.4 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.6.5 Bayer HealthCare Key News
- 7.7 Bristol-Myers Squibb
  - 7.7.1 Bristol-Myers Squibb Corporate Summary
  - 7.7.2 Bristol-Myers Squibb Business Overview
  - 7.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.7.4 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.7.5 Bristol-Myers Squibb Key News
- 7.8 Valeant Pharmaceuticals
  - 7.8.1 Valeant Pharmaceuticals Corporate Summary
  - 7.8.2 Valeant Pharmaceuticals Business Overview
  - 7.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.8.4 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.8.5 Valeant Pharmaceuticals Key News
- 7.9 Endo Pharmaceuticals
  - 7.9.1 Endo Pharmaceuticals Corporate Summary

- 7.9.2 Endo Pharmaceuticals Business Overview
- 7.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
- 7.9.4 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
- 7.9.5 Endo Pharmaceuticals Key News
- 7.10 Foresee Pharmaceuticals
  - 7.10.1 Foresee Pharmaceuticals Corporate Summary
  - 7.10.2 Foresee Pharmaceuticals Business Overview
  - 7.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.10.4 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.10.5 Foresee Pharmaceuticals Key News
- 7.11 Merck
  - 7.11.1 Merck Corporate Summary
  - 7.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Business Overview
  - 7.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.11.4 Merck Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.11.5 Merck Key News
- 7.12 Novartis
  - 7.12.1 Novartis Corporate Summary
  - 7.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Business Overview
  - 7.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.12.4 Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.12.5 Novartis Key News
- 7.13 Advaxis
  - 7.13.1 Advaxis Corporate Summary
  - 7.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Business Overview
  - 7.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.13.4 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.13.5 Advaxis Key News
- 7.14 Teva Pharmaceutical Industries
  - 7.14.1 Teva Pharmaceutical Industries Corporate Summary

- 7.14.2 Teva Pharmaceutical Industries Business Overview
- 7.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
- 7.14.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
- 7.14.5 Teva Pharmaceutical Industries Key News
- 7.15 Urologixs
  - 7.15.1 Urologixs Corporate Summary
  - 7.15.2 Urologixs Business Overview
  - 7.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.15.4 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.15.5 Urologixs Key News
- 7.16 Agennix
  - 7.16.1 Agennix Corporate Summary
  - 7.16.2 Agennix Business Overview
  - 7.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.16.4 Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.16.5 Agennix Key News
- 7.17 ANI Pharmaceuticals
  - 7.17.1 ANI Pharmaceuticals Corporate Summary
  - 7.17.2 ANI Pharmaceuticals Business Overview
  - 7.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.17.4 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.17.5 ANI Pharmaceuticals Key News
- 7.18 BHR Pharma
  - 7.18.1 BHR Pharma Corporate Summary
  - 7.18.2 BHR Pharma Business Overview
  - 7.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.18.4 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.18.5 BHR Pharma Key News
- 7.19 Boehringer Ingelheim

- 7.19.1 Boehringer Ingelheim Corporate Summary
- 7.19.2 Boehringer Ingelheim Business Overview
- 7.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
- 7.19.4 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
- 7.19.5 Boehringer Ingelheim Key News
- 7.20 Sanpower Group
  - 7.20.1 Sanpower Group Corporate Summary
  - 7.20.2 Sanpower Group Business Overview
  - 7.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.20.4 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.20.5 Sanpower Group Key News
- 7.21 Eisai
  - 7.21.1 Eisai Corporate Summary
  - 7.21.2 Eisai Business Overview
  - 7.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.21.4 Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.21.5 Eisai Key News
- 7.22 Ferring
  - 7.22.1 Ferring Corporate Summary
  - 7.22.2 Ferring Business Overview
  - 7.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.22.4 Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.22.5 Ferring Key News
- 7.23 IO THERAPEUTICS
  - 7.23.1 IO THERAPEUTICS Corporate Summary
  - 7.23.2 IO THERAPEUTICS Business Overview
  - 7.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.23.4 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.23.5 IO THERAPEUTICS Key News
- 7.24 LIDDS
  - 7.24.1 LIDDS Corporate Summary

- 7.24.2 LIDDS Business Overview
- 7.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
- 7.24.4 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
- 7.24.5 LIDDS Key News
- 7.25 Madrigal Pharmaceuticals
  - 7.25.1 Madrigal Pharmaceuticals Corporate Summary
  - 7.25.2 Madrigal Pharmaceuticals Business Overview
  - 7.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.25.4 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.25.5 Madrigal Pharmaceuticals Key News
- 7.26 Nymox Pharmaceutical
  - 7.26.1 Nymox Pharmaceutical Corporate Summary
  - 7.26.2 Nymox Pharmaceutical Business Overview
  - 7.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.26.4 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.26.5 Nymox Pharmaceutical Key News
- 7.27 Spectrum Pharmaceuticals
  - 7.27.1 Spectrum Pharmaceuticals Corporate Summary
  - 7.27.2 Spectrum Pharmaceuticals Business Overview
  - 7.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.27.4 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.27.5 Spectrum Pharmaceuticals Key News
- 7.28 Takeda Pharmaceuticals
  - 7.28.1 Takeda Pharmaceuticals Corporate Summary
  - 7.28.2 Takeda Pharmaceuticals Business Overview
  - 7.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Major Product Offerings
  - 7.28.4 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales and Revenue in Global (2017-2022)
  - 7.28.5 Takeda Pharmaceuticals Key News

## **8 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION**



## **PRODUCTION CAPACITY, ANALYSIS**

8.1 Global Benign Prostatic Hyperplasia (BPH) Medication Production Capacity, 2017-2028

8.2 Benign Prostatic Hyperplasia (BPH) Medication Production Capacity of Key Manufacturers in Global Market

8.3 Global Benign Prostatic Hyperplasia (BPH) Medication Production by Region

## **9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS**

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

## **10 BENIGN PROSTATIC HYPERPLASIA (BPH) MEDICATION SUPPLY CHAIN ANALYSIS**

10.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Value Chain

10.2 Benign Prostatic Hyperplasia (BPH) Medication Upstream Market

10.3 Benign Prostatic Hyperplasia (BPH) Medication Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Benign Prostatic Hyperplasia (BPH) Medication Distributors and Sales Agents in Global

## **11 CONCLUSION**

## **12 APPENDIX**

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Key Players of Benign Prostatic Hyperplasia (BPH) Medication in Global Market

Table 2. Top Benign Prostatic Hyperplasia (BPH) Medication Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Share by Companies, 2017-2022

Table 5. Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Companies, (KG), 2017-2022

Table 6. Global Benign Prostatic Hyperplasia (BPH) Medication Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Price (2017-2022) & (USD/KG)

Table 8. Global Manufacturers Benign Prostatic Hyperplasia (BPH) Medication Product Type

Table 9. List of Global Tier 1 Benign Prostatic Hyperplasia (BPH) Medication Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Benign Prostatic Hyperplasia (BPH) Medication Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2017-2022

Table 15. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2023-2028

Table 16. By Application – Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication

Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2017-2022

Table 20. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2023-2028

Table 21. By Region – Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2017-2022

Table 25. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), 2023-2028

Table 26. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2017-2022

Table 29. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2023-2028

Table 30. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2017-2022

Table 33. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2023-2028

Table 34. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2017-2022

Table 37. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2023-2028

Table 38. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2017-2022

Table 41. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2023-2028

Table 42. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2017-2022

Table 45. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales, (KG), 2023-2028

Table 46. Astellas Pharma Corporate Summary

Table 47. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 48. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 49. Eli Lilly Corporate Summary

Table 50. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 51. Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 52. GlaxoSmithKline Corporate Summary

Table 53. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 54. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 55. Sanofi Corporate Summary

Table 56. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 57. Sanofi Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 58. ADC Therapeutics Corporate Summary

Table 59. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 60. ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 61. Bayer HealthCare Corporate Summary

Table 62. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 63. Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 64. Bristol-Myers Squibb Corporate Summary

Table 65. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 66. Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 67. Valeant Pharmaceuticals Corporate Summary

Table 68. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 69. Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 70. Endo Pharmaceuticals Corporate Summary

Table 71. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 72. Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 73. Foresee Pharmaceuticals Corporate Summary

Table 74. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 75. Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 76. Merck Corporate Summary

Table 77. Merck Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 78. Merck Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 79. Novartis Corporate Summary

Table 80. Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 81. Novartis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 82. Advaxis Corporate Summary

Table 83. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 84. Advaxis Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 85. Teva Pharmaceutical Industries Corporate Summary

Table 86. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH)

## Medication Product Offerings

Table 87. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 88. Urologixs Corporate Summary

Table 89. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 90. Urologixs Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 91. Agennix Corporate Summary

Table 92. Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 93. Agennix Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 94. ANI Pharmaceuticals Corporate Summary

Table 95. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 96. ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 97. BHR Pharma Corporate Summary

Table 98. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 99. BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 100. Boehringer Ingelheim Corporate Summary

Table 101. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 102. Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 103. Sanpower Group Corporate Summary

Table 104. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 105. Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 106. Eisai Corporate Summary

Table 107. Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 108. Eisai Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

Table 109. Ferring Corporate Summary

Table 110. Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Offerings

Table 111. Ferring Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)

- Table 112. IO THERAPEUTICS Corporate Summary
- Table 113. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 114. IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 115. LIDDS Corporate Summary
- Table 116. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 117. LIDDS Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 118. Madrigal Pharmaceuticals Corporate Summary
- Table 119. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 120. Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 121. Nymox Pharmaceutical Corporate Summary
- Table 122. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 123. Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 124. Spectrum Pharmaceuticals Corporate Summary
- Table 125. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 126. Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 127. Takeda Pharmaceuticals Corporate Summary
- Table 128. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Offerings
- Table 129. Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Sales (KG), Revenue (US\$, Mn) and Average Price (USD/KG) (2017-2022)
- Table 130. Benign Prostatic Hyperplasia (BPH) Medication Production Capacity (KG) of Key Manufacturers in Global Market, 2020-2022 (KG)
- Table 131. Global Benign Prostatic Hyperplasia (BPH) Medication Capacity Market Share of Key Manufacturers, 2020-2022
- Table 132. Global Benign Prostatic Hyperplasia (BPH) Medication Production by Region, 2017-2022 (KG)
- Table 133. Global Benign Prostatic Hyperplasia (BPH) Medication Production by Region, 2023-2028 (KG)
- Table 134. Benign Prostatic Hyperplasia (BPH) Medication Market Opportunities & Trends in Global Market

Table 135. Benign Prostatic Hyperplasia (BPH) Medication Market Drivers in Global Market

Table 136. Benign Prostatic Hyperplasia (BPH) Medication Market Restraints in Global Market

Table 137. Benign Prostatic Hyperplasia (BPH) Medication Raw Materials

Table 138. Benign Prostatic Hyperplasia (BPH) Medication Raw Materials Suppliers in Global Market

Table 139. Typical Benign Prostatic Hyperplasia (BPH) Medication Downstream

Table 140. Benign Prostatic Hyperplasia (BPH) Medication Downstream Clients in Global Market

Table 141. Benign Prostatic Hyperplasia (BPH) Medication Distributors and Sales Agents in Global Market



## List Of Figures

### LIST OF FIGURES

- Figure 1. Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
- Figure 2. Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
- Figure 3. Global Benign Prostatic Hyperplasia (BPH) Medication Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Benign Prostatic Hyperplasia (BPH) Medication Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Benign Prostatic Hyperplasia (BPH) Medication Revenue, 2017-2028 (US\$, Mn)
- Figure 7. Benign Prostatic Hyperplasia (BPH) Medication Sales in Global Market: 2017-2028 (KG)
- Figure 8. The Top 3 and 5 Players Market Share by Benign Prostatic Hyperplasia (BPH) Medication Revenue in 2021
- Figure 9. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028
- Figure 10. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028
- Figure 11. By Type - Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG), 2017-2028
- Figure 12. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028
- Figure 13. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028
- Figure 14. By Application - Global Benign Prostatic Hyperplasia (BPH) Medication Price (USD/KG), 2017-2028
- Figure 15. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028
- Figure 16. By Region - Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028
- Figure 17. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028
- Figure 18. By Country - North America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028
- Figure 19. US Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028
- Figure 20. Canada Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$,

Mn), 2017-2028

Figure 21. Mexico Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

Figure 24. Germany Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 25. France Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

Figure 33. China Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 37. India Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

Figure 39. By Country - South America Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

Figure 40. Brazil Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share, 2017-2028

Figure 44. Turkey Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Benign Prostatic Hyperplasia (BPH) Medication Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Benign Prostatic Hyperplasia (BPH) Medication Production Capacity (KG), 2017-2028

Figure 49. The Percentage of Production Benign Prostatic Hyperplasia (BPH) Medication by Region, 2021 VS 2028

Figure 50. Benign Prostatic Hyperplasia (BPH) Medication Industry Value Chain

Figure 51. Marketing Channels

## I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Medication Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/B845A5150755EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B845A5150755EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

